TABLE 4

Pharmacokinetic parameters and analysis for dihydroartemisinin and piperaquine following administration of dihydroartemisinin-piperaquine with or without tafenoquinea

Analyte and treatment group or parameterGeometric mean AUC0–τ (ng · h/ml)Geometric mean AUC0–last (ng · h/ml)Geometric mean Cmax (ng/ml)Geometric mean t1/2 (h)Median Tmax (h) (range)
Dihydroartemisinin
    TQ + DHA-PQP (n = 24)761.2748.9262.51.72.0 (1.0–6.0)
    DHA-PQP (n = 23)758.0749.5277.51.62.0 (1.0–6.0)
    CVb (%)44.043.950.936.7
    Ratio (90% CI)1.00 (0.82, 1.24)1.00 (0.81, 1.23)0.95 (0.75, 1.20)1.05 (0.88, 1.25)
Piperaquine
    TQ + DHA-PQP (n = 24)9,206.535,660.1840.5360.44.0 (3.0–8.0)
    DHA-PQP (n = 23)9,815.637,358.0928.2382.24.0 (3.0–8.0)
    CVb (%)30.232.536.889.5
    Ratio (90% CI)0.94 (0.81, 1.08)0.95 (0.82, 1.11)0.91 (0.76, 1.08)0.94 (0.65, 1.37)
  • a CVb, between-subject variability.